Floatz logo

Lorigerlimab

Clear Cell Adenocarcinoma of Peritoneum

MacroGenicsmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Clear Cell Adenocarcinoma of Peritoneum cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BBB
Inno-206
Eli Lilly and Company
Phase 3BBB
FLUOROURACILUM
AstraZeneca
Phase 2BB
Eloxatin
Sun Yat-sen University
Phase 2/3BB
Patupilone
Novartis Pharmaceuticals
Phase 3BB

View all 44 →

Same molecule, other indications

Lorigerlimab is also rated in:

castration-resistant prostate carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
prostate cancerDormant
B
Indicative ·
57 / 100
View asset →
Immune Checkpoint InhibitorDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →